BIOVENTUS INC - A (BVS) Stock Overview
NASDAQ:BVS - US09075A1088 - Common Stock
BVS Key Statistics, Chart & Performance
The current stock price of BVS is 7.44 USD. In the past month the price increased by 13.94%. In the past year, price decreased by -25.97%.
BVS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ALC | ALCON INC | 26.92 | 40.36B | ||
| COO | COOPER COS INC/THE | 18.94 | 14.66B | ||
| SOLV | SOLVENTUM CORP | 11.97 | 12.61B | ||
| ALGN | ALIGN TECHNOLOGY INC | 15.4 | 10.51B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 24.09 | 5.22B | ||
| BLCO | BAUSCH + LOMB CORP | 34.6 | 5.14B | ||
| LNTH | LANTHEUS HOLDINGS INC | 8.79 | 3.82B | ||
| ICUI | ICU MEDICAL INC | 16.73 | 3.11B | ||
| XRAY | DENTSPLY SIRONA INC | 8.42 | 2.87B | ||
| HAE | HAEMONETICS CORP/MASS | 11.88 | 2.66B | ||
| UFPT | UFP TECHNOLOGIES INC | 25.6 | 1.70B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.35B |
Related stock screener links
About BVS
Company Profile
Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 930 full-time employees. The company went IPO on 2021-02-11. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. The company offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
Company Info
BIOVENTUS INC - A
4721 Emperor Boulevard, Suite 100
Durham NORTH CAROLINA 27703 US
CEO: Kenneth M. Reali
Employees: 950
Phone: 19194746700
BIOVENTUS INC - A / BVS FAQ
What is the stock price of BIOVENTUS INC - A today?
The current stock price of BVS is 7.44 USD. The price decreased by -2.62% in the last trading session.
What is the ticker symbol for BIOVENTUS INC - A stock?
The exchange symbol of BIOVENTUS INC - A is BVS and it is listed on the Nasdaq exchange.
On which exchange is BVS stock listed?
BVS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIOVENTUS INC - A stock?
8 analysts have analysed BVS and the average price target is 14.28 USD. This implies a price increase of 91.94% is expected in the next year compared to the current price of 7.44. Check the BIOVENTUS INC - A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOVENTUS INC - A worth?
BIOVENTUS INC - A (BVS) has a market capitalization of 615.14M USD. This makes BVS a Small Cap stock.
How many employees does BIOVENTUS INC - A have?
BIOVENTUS INC - A (BVS) currently has 950 employees.
What are the support and resistance levels for BIOVENTUS INC - A (BVS) stock?
BIOVENTUS INC - A (BVS) has a support level at 7.1 and a resistance level at 7.65. Check the full technical report for a detailed analysis of BVS support and resistance levels.
Is BIOVENTUS INC - A (BVS) expected to grow?
The Revenue of BIOVENTUS INC - A (BVS) is expected to grow by 0.06% in the next year. Check the estimates tab for more information on the BVS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIOVENTUS INC - A (BVS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BVS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BVS, evaluating the profitability, health, valuation and growth aspects
- BIOVENTUS INC - A (BVS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOVENTUS INC - A (BVS) Sales and EPS estimates to see what analysts future expectations are.
- BIOVENTUS INC - A (BVS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOVENTUS INC - A (BVS) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOVENTUS INC - A (BVS) Stock Chart to make your own analysis
- BIOVENTUS INC - A (BVS) Latest news and press-releases to stay up to date.
Does BIOVENTUS INC - A (BVS) stock pay dividends?
BVS does not pay a dividend.
When does BIOVENTUS INC - A (BVS) report earnings?
BIOVENTUS INC - A (BVS) will report earnings on 2025-11-03, before the market open.
What is the Price/Earnings (PE) ratio of BIOVENTUS INC - A (BVS)?
The PE ratio for BIOVENTUS INC - A (BVS) is 14.88. This is based on the reported non-GAAP earnings per share of 0.5 and the current share price of 7.44 USD. Check the full fundamental report for a full analysis of the valuation metrics for BVS.
What is the Short Interest ratio of BIOVENTUS INC - A (BVS) stock?
The outstanding short interest for BIOVENTUS INC - A (BVS) is 3.08% of its float. Check the ownership tab for more information on the BVS short interest.
BVS Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to BVS. When comparing the yearly performance of all stocks, BVS is a bad performer in the overall market: 79.01% of all stocks are doing better.
BVS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BVS. While BVS is still in line with the averages on profitability rating, there are concerns on its financial health.
BVS Financial Highlights
Over the last trailing twelve months BVS reported a non-GAAP Earnings per Share(EPS) of 0.5. The EPS increased by 31.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.02% | ||
| ROE | -0.1% | ||
| Debt/Equity | 1.9 |
BVS Forecast & Estimates
8 analysts have analysed BVS and the average price target is 14.28 USD. This implies a price increase of 91.94% is expected in the next year compared to the current price of 7.44.
For the next year, analysts expect an EPS growth of 38.25% and a revenue growth 0.06% for BVS